Sustained Specific EBOV GP Immunogenicity Five-Years Post-Vaccination: Longitudinal Results from North Kivu and Equateur, Democratic Republic of the Congo
Five years after receiving the rVSV-ZEBOV-GP vaccine during the 2018 Ebola outbreaks in the Democratic Republic of the Congo, a longitudinal study of 1,081 individuals demonstrated that the majority retained sustained detectable anti-EBOV GP antibodies, with response durability varying by prior exposure history and booster administration.